Gameto: Funding, Investors & Team (Sep 2026)
Gameto is a biotechnology company focused on revolutionizing women's reproductive health through the development of innovative therapies. They aim to address the lack of effective treatment options for various female health conditions by using advanced scientific techniques. Through cellular engineering, Gameto has created female reproductive cell lines that closely resemble natural cells, enabling them to develop new therapeutic solutions. Their initial program, Fertilo, aims to enhance the outcomes of IVF and egg freezing procedures. In addition, they are working on developing an organoid of the female reproductive system called Deovo, as well as a cell-based therapy for primary ovarian insufficiency and menopause called Ameno. Gameto's team is dedicated to pushing the boundaries of medical technology to improve the lives of women everywhere.
Gameto has raised $114M across 4 funding rounds on record, the most recent a Series C of $44.0M announced in Aug 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Gameto Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Gameto Funding Rounds
Gameto raised $20.0M in a Series A announced in Jan 2022.
8 months later, an undisclosed round of $17.0M was announced in Sep 2022.
1.7 years later, a Series B of $33.0M was announced in May 2024.
1.3 years later, a Series C of $44.0M was announced in Aug 2025.
Gameto Founders and Leadership Team
Contact details for the Gameto team: 1 of 3 have an email address on file.
Start 14-day free trial →Gameto Funding Compared to Other Biotechnology Startups
Gameto's latest round of $44.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Gameto in Biotechnology and New York
Companies Similar to Gameto
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Gameto Funding FAQs
What does Gameto do?
Gameto is a biotechnology company focused on revolutionizing women's reproductive health through the development of innovative therapies. They aim to address the lack of effective treatment options for various female health conditions by using advanced scientific techniques. Through cellular engineering, Gameto has created female reproductive cell lines that closely resemble natural cells, enabling them to develop new therapeutic solutions. Their initial program, Fertilo, aims to enhance the outcomes of IVF and egg freezing procedures. In addition, they are working on developing an organoid of the female reproductive system called Deovo, as well as a cell-based therapy for primary ovarian insufficiency and menopause called Ameno. Gameto's team is dedicated to pushing the boundaries of medical technology to improve the lives of women everywhere.
How much funding has Gameto raised?
Gameto has raised $114M across 4 rounds on record. The most recent is a Series C of $44.0M announced in Aug 2025.
When did Gameto last raise funding?
Gameto's most recent funding round on record is a Series C of $44.0M, announced in Aug 2025.
Who founded Gameto?
FundedIQ lists Martin Varsavsky (Founder), Pranam Chatterjee (Founder) at Gameto.
Who is the CEO of Gameto?
Dina Radenkovic is listed as CEO at Gameto.
Where is Gameto headquartered?
Gameto is based in New York, New York, United States.
How many employees does Gameto have?
Gameto is in the 11-50 employee band.
How does Gameto's funding compare to other Biotechnology startups?
Gameto's latest round of $44.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Gameto Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Gameto is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.